title: Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy.
abstract: 30 ovarian cancer patients with a relapse after prior cisplatin combination chemotherapy were treated in a phase II study with cyclophosphamide 100 mg/m2 orally on days 1-7 and carboplatin 300 mg/m2 intravenously on day 8. Treatment was well tolerated. The major side-effect was thrombocytopenia. 28 patients were evaluable for response. The response was 5 CRs (18%), 4 PRs (14%) 15 SDs (53%) and 4 PDs (14%), for an overall response rate of 32%. The overall progression-free survival lasted from 2 to 23 months, median 8 months. Overall survival ranged from 2 to 35+ months, median 12 months. Patients with a therapy-free interval of more than 1 year showed a higher response rate (46%) than patients with a shorter therapy-free interval (20%). It is concluded that platinum containing second-line chemotherapy, after treatment that already contained cisplatin, is only warranted to palliate symptoms.
authors.affiliation: Department of Medical Oncology, Rotterdam Cancer Institute, Daniel de Hoed Kliniek, The Netherlands.
authors.forename: M E
authors.initials: ME
authors.lastname: van der Burg
authors.forename: A M
authors.initials: AM
authors.lastname: Hoff
authors.forename: M
authors.initials: M
authors.lastname: van Lent
authors.forename: C J
authors.initials: CJ
authors.lastname: Rodenburg
authors.forename: W L
authors.initials: WL
authors.lastname: van Putten
authors.forename: G
authors.initials: G
authors.lastname: Stoter
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011379:Prognosis; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D003520:Cyclophosphamide; D016190:Carboplatin; D002945:Cisplatin